NewMed Energy – Limited Partnership

(the "**Partnership**")

3 September 2026

To
The Israel Securities Authority
22 Kanfei Nesharim Street
Jerusalem
Via Magna

To
The Tel Aviv Stock Exchange Ltd.
2 Ahuzat Bayit Street
Tel Aviv
Via Magna

Dear Sir/Madam,

Re: **Potential Bond Issuance – Notice of Results of an Institutional Tender**

Further to the Partnership's immediate reports of 13 August 2026, 25 August 2026, 31 August 2026 and 1 September 2026 (Refs. 2026-01-075878, 2026-01-079960, 2026-01-081759 and 2026-01-082645, respectively) regarding its intention to carry out, by way of a uniform offering, a public issuance of two new bond series of the Partnership, Series B Bonds and Series C Bonds, which shall be listed for trading on the Tel Aviv Stock Exchange Ltd. ("**TASE**"), pursuant to a shelf offering report, if and to the extent published by the Partnership (the ""**Shelf Offering Report**"), and the Partnership's shelf prospectus of 12 May 2025 dated 13 May 2025 (Ref. 2025-01-033082), the Partnership respectfully reports that, on 2 September 2026, a tender was held for the receipt of early commitments from accredited investors [1] in connection with a potential issuance of Series B Bonds and Series C Bonds (the "**Institutional Tender**" and "**Accredited Investors**", respectively). The results of the Institutional Tender are presented below.

1. **Series B Bonds**

Series B Bonds were offered in the Institutional Tender to Accredited Investors by way of tender for the interest rate on the bonds, with each unit consisting of ILS 1,000 par value of Series B Bonds. In the Institutional Tender, early commitments to acquire 2,384,156 units of Series B Bonds in the total amount of ILS 2,384,156,000 were received from Accredited Investors. The Partnership intends to accept early commitments by Accredited Investors to acquire 1,750,984 units of Series B Bonds consisting of ILS 1,750,984,000 par value of Series B Bonds (among other things, subject to approval by the rating agency), at a maximum interest rate per annum of 4.54%, which shall represent the maximum interest rate for Series B Bonds in the public tender (insofar as held).

[1] Within the definition of the term "accredited investor" in the Securities Regulations (Manner of Offering Securities to the Public), 5767-2007.

2. <u>**Series C Bonds**</u>

In view of the demand in the institutional tender as described above, the Company intends to offer the public only Series B Bonds, and not offer the public Series C Bonds.

It is clarified that there is no certainty that the issuance of Series B Bonds will take place, and nothing in the foregoing shall create any undertaking on the part of the Partnership to carry out the issuance of Series B Bonds. The publication of the Shelf Offering Report and the conduct of the issuance are subject to the receipt of all the approvals required by law and to approval by TASE of the listing of Series B Bonds (if offered) for trading.

Nothing herein shall create any undertaking by the Partnership to conduct the issuance of Series B Bonds, and nothing herein shall constitute a public offering of and/or an invitation to acquire securities of the Partnership.

Sincerely,

NewMed Energy Management Ltd.

General Partner in NewMed Energy – Limited Partnership

By Niv Sarne, CEO

Sari Singer Kaufman, General Counsel, Senior VP